Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
RNA-based Therapies Market to Reach USD 213.54 Billion by 2033, Driven by Rare…
However, the industry faces challenges such as high development costs, scalability hurdles, stringent regulatory pathways, and safety concerns. Despite these restraints, opportunities are expanding in oncology, cardiometabolic disorders, immunology, and rare diseases, driven by innovations such as self-amplifying RNA and small activating RNA platforms. However, the industry faces challenges such ashigh development costs, scalability hurdles, stringent regulatory pathways, and safety concerns...
PR Newswire
22/09/2025
Angelini Pharma Signs Exclusive Option Agreement With Sovargen To License Global…
Angelini Pharma secures exclusive option to license global development and commercialization rights for SVG105 1, a pre-clinical investigational novel compound with broad potential to treat brain health diseases, excluding the Republic of Korea, China, Hong Kong, Macau and TaiwanSovargen receives upfront payment and is eligible for future milestone-dependent payments and royaltiesAgreement further expands Angelini Pharma’s strong portfolio and deep therapeutic expertise in brain health,...
Nasdaq GlobeNewswire
22/09/2025
Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple…
Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, commented: "Our participation in ECTRIMS reflects the company's commitment to advancing care in multiple sclerosis and our aspiration to expand access to innovative therapies. Providing differentiated products to patients and healthcare professionals across Europe and other markets is a key pillar of Neuraxpharm's growth strategy and allows us to continue strengthening our position as a CNS specialist." Dr. Jörg- Thomas Dierks, CEO of…
PR Newswire
22/09/2025
Antibiotics Market Size to Surpass USD 55.26 Billion by 2033, Report by DataM…
The rising prevalence of infectious diseases is significantly driving the global antibiotics market growth. The rising prevalence of infectious diseases is significantly driving the global antibiotics market growth. The growing incidence of infectious disorders like sepsis, pneumonia, TB, and UTIs is a major factor propelling the worldwide antibiotics market. There is a great need for efficient therapies since hospital-acquired infections, international travel, and growing urbanization...
PR Newswire
22/09/2025
Hon'ble CM of Delhi, Smt. Rekha Gupta, Inaugurates Apollo Athenaa - Asia's First…
In the recent past, more women than men have been diagnosed with cancer, notably with cancers in women accounting for the highest incidence. A new study from ICMR's National Cancer Registry Programme (NCRP) has revealed that breast and cervical cancers are the most common types of cancers among Indian women. In the recent past,more women than menhave been diagnosed with cancer, notably with cancers in women accounting for the highest incidence. A new study fromICMR's National Cancer...
PR Newswire
22/09/2025
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center…
LONDON and NEW YORK, Sept.22, 2025(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announced plans for the next stage of clinical development for its lead drug candidate, urcosimod, to treat neuropathic corneal pain (NCP).The...
Nasdaq GlobeNewswire
22/09/2025
Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market…
Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the commencement of its U.S. operations with the launch of its proprietary Sky Premium Life food supplements brand.All Sky Premium Life products sold in the United States are manufactured locally in GMP-certified, FDA-registered, and UL-audited U.S. facilities, underscoring the Company’s commitment to regulatory excellence and...
Nasdaq GlobeNewswire
22/09/2025
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of…
As part of the agreement, SOPHiA GENETICS will roll out a Privileged Access Program to selected clinical laboratories specializing in breast and prostate cancer research to validate sensitivity in a real-world setting, with broader commercial availability expected in 2026, alongside a multi-center real-world evidence study to further test its effectiveness. SOPHiA GENETICS's global network will also help drive adoption of advanced PIK3CA/AKT1/PTEN testing in both tissue and liquid biopsy to…
PR Newswire
22/09/2025
Lusochimica S.p.A. (Menarini Group) awarded by the European Commission with the…
The SmartNEBI project is managed by HaDEA, an executive agency of the European Commission, and funded under EU4Health, the EU funding programme designed, amongst other objectives, to tackle cross-border health challenges through high-quality, innovative projects in the health sector. This endorsement highlights SmartNEBI's strategic contribution to the objectives of the Strategic Technologies for Europe Platform (STEP) and recognizes its value for Europe's technological and industrial…
PR Newswire
22/09/2025
Beauty and Well-being Businesses Looking to Expand Product Portfolio Will Be…
COSMEX will also house COSMEX The Secret Chat, seminars and workshops designed to share insights, ideas, skills, and inspiration. COSMEX will also houseCOSMEX The Secret Chat, seminars and workshops designed to share insights, ideas, skills, and inspiration. COSMEX is co-located within-cosmeticsAsia , the leading event inAsia Pacificfor personal care ingredients. Pre-registration is available atwww.cosmexshow.com. For inquiries, email
[email protected]
...
PR Newswire
22/09/2025
European Medicines Agency Recommends Marketing Authorization of AVT03…
REYKJAVIK, ICELAND (September 22, 2024)— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) has adopted a positive opinion recommending approval for AVT03, Alvotech’s proposed biosimilar to Prolia® (denosumab 60 mg/mL single use pre-filed syringe) and Xgeva® (denosumab 70 mg/mL single use…
Nasdaq GlobeNewswire
22/09/2025
First European Participants Randomized in AskBio Phase 2 Gene Therapy Trial of…
Research Triangle Park, N.C., Sept.22, 2025(GLOBE NEWSWIRE) -- AB-1005, a glial cell line-derived neurotrophic factor (GDNF) investigational gene therapy, is being evaluated for the treatment of moderate-stage Parkinson’s disease in the REGENERATE-PD trial Sites in Poland and the United Kingdom have started randomizing participants, with sites in Germany actively screening and following shortly AskBio initiated recruitment in the United States in 2024 , with...
Nasdaq GlobeNewswire
22/09/2025
Biotic innovation tackles iron deficiency in women - now recognized across three…
Iron deficiency is one of the world's most pressing nutritional challenges, affecting over 30% of women of reproductive age globally. Rather than simply adding more iron, Probi's patented strain helps the body absorb it more effectively. LP299V® supports iron uptake in two key ways: by keeping iron in its absorbable form and by increasing the body's expression of iron-converting enzymes. This leads to better absorption from food and supplements. "Recognition across three...
PR Newswire
22/09/2025
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s…
REYKJAVIK, ICELAND and LONDON, UK (September 22, 2025)— Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use...
Nasdaq GlobeNewswire
22/09/2025
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor…
Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked TrialOculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the upcoming presentation of the positive Phase 2 ACUITY trial results investigating...
Nasdaq GlobeNewswire
22/09/2025
Sweet Tooth by Sabrina Carpenter Fragrances Now Shipping Direct-to-Consumer in…
"At Scent Beauty, we're committed to delivering the best fragrance and beauty experiences to consumers around the world," says Steve Mormoris, CEO of Scent Beauty. "We believe everyone deserves easy, affordable, and environmentally responsible ways to shop. We are excited to announce that Sabrina Carpenter's Sweet Tooth fragrance line now ships directly to customers in the UK and European Union, fulfilled from regional warehouses. We are proud to be a first-mover in this space…
PR Newswire
22/09/2025
Amorepacific Presents AI-based Skin Science Innovations and Findings at IFSCC…
Established in 1959, the IFSCC Congress is the world's largest cosmetics science conference serving as a forum for leading cosmetic researchers around the world. This year's event, themed "The Future is Science," featured two oral presentations and five poster presentations by Amorepacific researchers, aimed at further accelerating biological research on aging and integration of AI in driving scientific advancements. Established in 1959, the IFSCC Congress is the world's largest…
PR Newswire
22/09/2025
BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief…
®Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, called YntraDose ®, announced today the succession of its Chief Executive Officer (“CEO”), Dr. Colin Story, to Mr. Alexis Peyroles, who was appointed as CEO. Mr. Peyroles served as Board member since May 19, 2025.“We are pleased to welcome Alexis as BetaGlue’s new CEO, given his deep...
Nasdaq GlobeNewswire
22/09/2025
Hon'ble CM of Delhi, Smt. Rekha Gupta, Inaugurates Apollo Athenaa - Asia's First…
In the recent past, more women than men have been diagnosed with cancer, notably with cancers in women accounting for the highest incidence. A new study from ICMR's National Cancer Registry Programme (NCRP) has revealed that breast and cervical cancers are the most common types of cancers among Indian women. In the recent past,more women than menhave been diagnosed with cancer, notably with cancers in women accounting for the highest incidence. A new study fromICMR's National Cancer...
PR Newswire
22/09/2025
Wholesale Platform SUPER DELIVERY to Host Special Promotion Showcasing Matcha…
Rising Global Demand for MatchaDriven by inbound tourism, a weaker yen, and a worldwide wellness trend, matcha has seen remarkable growth overseas. On SUPER DELIVERY, orders for Japanese tea utensils have surged 2.2 times year-on-year, with particularly strong demand from the United States and Australia. Rising Global Demand for Matcha Driven by inbound tourism, a weaker yen, and a worldwide wellness trend, matcha has seen remarkable growth overseas. On SUPER DELIVERY, orders for Japanese tea...
PR Newswire
22/09/2025
TransMedics and Mercedes-Benz Announce Strategic Collaboration to Launch First…
ANDOVER, Mass., Sept. 22, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced a strategic collaboration with Mercedes-Benz Group AG to deploy a first-of-its-kind fleet of modern, purpose-built Mercedes-Benz V-class vehicles dedicated exclusively to organ transportation across Italy. ANDOVER, Mass. , Sept. 22…
PR Newswire
22/09/2025
Two International Proxy Advisory Firms Support the Governance Project Proposed…
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at theSeptember 30 thGeneral MeetingNANTES, France – September 22, 2025, 8:00 a.m. CET – OSE Immunotherapeutics SA(ISIN: FR0012127173; Mnemo: OSE) announces that two international proxy advisory firms, including Glass Lewis, recommend shareholders to vote IN FAVOR of the resolutions proposed by the Board of Directors regarding its composition (resolutions 5 to 8) at the...
Nasdaq GlobeNewswire
22/09/2025
KLEA HOLDING (ex VISIOMED GROUP) : Klea Holding significantly improves its…
+46% growth in half-yearly revenue, driven by an increase in the number of tests. +118% growth in normalised EBITDA (€3.9m), representing a normalised margin of 33.8%. €2.6m in consolidated EBITDA and €1.1m in consolidated net profit (Group share). €3.2m in gross cash and net financial debt of only €1.9m…
Actusnews Wire
22/09/2025
CROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and…
Press releaseCROSSJECT Secures Additional BARDA Funding for the Progressive Developmental and FDA Authorization of the ZEPIZURE® (ZENEO® Midazolam)DIJON, France – September 22, 2025 (7.30 AM CET) – CROSSJECT(ISIN: FR0011716265; Euronext: ALCJ), the global specialty pharma company developing needle-free auto-injectors for emergency situations, today confirms an additional $11.3 million in funding awarded by the U.S. Biomedical Advanced Research and Development Authority (BARDA)...
Nasdaq GlobeNewswire
22/09/2025
Altri Comunicati
